Incidence and Predictors of Very Late (≥4 Years) Major Cardiac Adverse Events in the DESIRE (Drug-Eluting Stents in the Real World)-Late Registry

JACC: Cardiovascular Interventions

Volumn 3, Issue 1, 2010, Pages 12-18

  Costa Jr , J Ribamar ^a   Sousa, Amanda ^a   Moreira, Adriana C ^a   Costa, Ricardo A ^a   Cano, Manuel ^a   Maldonado, Galo ^a   Campos, Cantídio ^a   Carballo, Mariana ^a   Pavanello, Ricardo ^a   Sousa, J Eduardo ^a  

^a Hospital do Coracao   (Brazil)

Author keywords

drug eluting stents; stent thrombosis; very long term outcomes

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; ADVERSE OUTCOME; ARTICLE; BLOOD VESSEL CALCIFICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE REGISTRY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART MUSCLE REVASCULARIZATION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STENT THROMBOSIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BRAZIL; CALCINOSIS; CARDIOVASCULAR AGENTS; CORONARY RESTENOSIS; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; HEART DISEASES; HUMANS; INCIDENCE; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PACLITAXEL; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 74049120470     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2009.10.022     Document Type: Article

References (10)

1. Lagerqvist B., James S.K., Stenestrand U., Lindbäck J., Nilsson T., Wallentin L., and SCAAR Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
2. Cook S., Wenaweser P., Togni M., et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 115 (2007) 2426-2434
3. Siqueira D.A., Abizaid A.A., Costa J.R., et al. Late incomplete apposition after drug-eluting stent implantation: incidence and potential for adverse clinical outcomes. Eur Heart J 28 (2007) 1304-1309
4. Cosgrave J., Qasim A., Latib A., Aranzulla T.C., and Colombo A. Very late restenosis after paclitaxel-eluting stent implantation. Ann Intern Med 147 (2007) 885-887
5. Cutlip D.E., Windecker S., Mehran R., et al., Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
6. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
7. Daemen J., Ong A.T., Stefanini G.G., et al. Three-year clinical follow-up of the unrestricted use of sirolimus-eluting stents as part of the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Am J Cardiol 98 (2006) 895-901
8. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
9. Wenaweser P., Daemen J., Zwahlen M., et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol 52 (2008) 1134-1140
10. Pfisterer M., Brunner-La Rocca H.P., Rickenbacher P., et al., BASKET Investigators. Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter?. Three-year follow-up of BASKET. Eur Heart J 30 (2009) 16-24